Literature DB >> 28705491

Proposal of selection criteria for operative resection of hepatocellular carcinoma with inferior vena cava tumor thrombus incorporating hepatic arterial infusion chemotherapy.

Yosuke Kasai1, Etsuro Hatano2, Satoru Seo1, Kojiro Taura1, Kentaro Yasuchika1, Hideaki Okajima1, Toshimi Kaido1, Shinji Uemoto1.   

Abstract

BACKGROUND: Because operative resection of hepatocellular carcinoma with inferior vena cava tumor thrombus has been associated with a substantial risk of recurrence and postoperative morbidity, adequate patient selection for resection is necessary. Our aim was to propose selection criteria for resection of hepatocellular carcinoma with inferior vena cava tumor thrombus.
METHODS: Long-term outcomes were analyzed retrospectively in 39 operative cases of hepatocellular carcinoma with inferior vena cava tumor thrombus (1996-2015). Since 2003, preoperative hepatic arterial infusion chemotherapy instead of immediate resection has been performed in patients with advanced inferior vena cava tumor thrombus, defined as those patients with suspected extrahepatic metastasis, who will need extracorporeal circulation, or who have marginal liver function and/or multiple bilobar tumors. Indication for resection has been based on the tumor response to hepatic arterial infusion chemotherapy thereafter.
RESULTS: The median survival time for all patients was 15.2 months. Multivariate analysis revealed that preoperative hepatic arterial infusion chemotherapy (hazard ratio: 0.30), use of extracorporeal circulation (3.12), and extrahepatic metastasis (2.67) were independent prognostic factors for overall survival. Among patients with initially advanced inferior vena cava tumor thrombus, preoperative hepatic arterial infusion chemotherapy was associated with a much more favorable prognosis compared with no hepatic arterial infusion chemotherapy (median survival time: unreached vs 8.3 months, P = .007). Overall survival was significantly worse in patients with uncontrolled, advanced inferior vena cava tumor thrombus than in those without advanced inferior vena cava tumor thrombus or with advanced inferior vena cava tumor thrombus controlled by preoperative hepatic arterial infusion chemotherapy (median survival time: 10.4 vs 26.1 months, P = .039).
CONCLUSION: An effective response to hepatic arterial infusion chemotherapy and subsequent operative resection salvaged patients with initially advanced inferior vena cava tumor thrombus. Our results suggest that operative resection should be indicated only in patients without advanced inferior vena cava tumor thrombus or with advanced inferior vena cava tumor thrombus controlled by preoperative hepatic arterial infusion chemotherapy.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28705491     DOI: 10.1016/j.surg.2017.05.011

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  9 in total

1.  Proton beam therapy for hepatocellular carcinoma associated with inferior vena cava tumor thrombus.

Authors:  Yuta Sekino; Toshiyuki Okumura; Nobuyoshi Fukumitsu; Takashi Iizumi; Haruko Numajiri; Masashi Mizumoto; Kei Nakai; Tetsuo Nonaka; Hitoshi Ishikawa; Hideyuki Sakurai
Journal:  J Cancer Res Clin Oncol       Date:  2019-11-27       Impact factor: 4.553

2.  Current trends in vena cava reconstructive techniques with major liver resection: a systematic review.

Authors:  Maria Baimas-George; Christoph Tschuor; Michael Watson; Jesse Sulzer; Patrick Salibi; David Iannitti; John B Martinie; Erin Baker; Pierre-Alain Clavien; Dionisios Vrochides
Journal:  Langenbecks Arch Surg       Date:  2020-09-26       Impact factor: 3.445

3.  A new classification for hepatocellular carcinoma with hepatic vein tumor thrombus.

Authors:  Zhen-Hua Chen; Kang Wang; Xiu-Ping Zhang; Jing-Kai Feng; Zong-Tao Chai; Wei-Xing Guo; Jie Shi; Meng-Chao Wu; Wan Yee Lau; Shu-Qun Cheng
Journal:  Hepatobiliary Surg Nutr       Date:  2020-12       Impact factor: 7.293

4.  Regression of Tumor Thrombus in the Suprahepatic Vena Cava of Hepatocellular Carcinoma and Conversion Hepatectomy Induced by Lenvatinib.

Authors:  Ryota Matsuki; Naohiro Okano; Takaaki Arai; Shinya Yoshiike; Masaharu Kogure; Yutaka Suzuki; Junji Shibahara; Junji Furuse; Yoshihiro Sakamoto
Journal:  Liver Cancer       Date:  2021-11-11       Impact factor: 12.430

5.  Transmediastinal, intrapericardial inferior vena cava approach based on anatomical landmarks for hepatectomy using total hepatic vascular exclusion.

Authors:  Taiji Tohyama; Kei Tamura; Akihiro Takai; Kazuhisa Nishimura; Teruhito Kido; Yasutsugu Takada
Journal:  Langenbecks Arch Surg       Date:  2021-08-24       Impact factor: 2.895

Review 6.  Combination therapy for advanced hepatocellular carcinoma: do we see the light at the end of the tunnel?

Authors:  Ti Zhang; Philippe Merle; Huaqi Wang; Haitao Zhao; Masatoshi Kudo
Journal:  Hepatobiliary Surg Nutr       Date:  2021-04       Impact factor: 8.265

7.  Nomogram for Predicting Long-Term Survival after Synchronous Resection for Hepatocellular Carcinoma and Inferior Vena Cava Tumor Thrombosis: A Multicenter Retrospective Study.

Authors:  Yannan Bai; Jiayi Wu; Yong Zeng; Jie Chen; Shuangjia Wang; Shi Chen; Funan Qiu; Songqiang Zhou; Shen You; Yifeng Tian; Yaodong Wang; Maolin Yan
Journal:  J Oncol       Date:  2020-04-08       Impact factor: 4.375

8.  Liver resection with thrombectomy for patients with hepatocellular carcinoma and tumour thrombus in the inferior vena cava or right atrium.

Authors:  S Matsukuma; H Eguchi; H Wada; T Noda; Y Shindo; Y Tokumitsu; H Matsui; H Takahashi; S Kobayashi; H Nagano
Journal:  BJS Open       Date:  2020-02-03

Review 9.  Neoadjuvant treatment strategies for hepatocellular carcinoma.

Authors:  Lei Xu; Lin Chen; Wei Zhang
Journal:  World J Gastrointest Surg       Date:  2021-12-27
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.